Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004988:Ethers, Cyclic / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D004376:Galactitol / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D008936:Mitolactol / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use*; D011929:Razoxane / Q000627:therapeutic use*; D013402:Sugar Alcohols / Q000627:therapeutic use*
D004988:Ethers, Cyclic; D010879:Piperazines; D013402:Sugar Alcohols; D004376:Galactitol; D011929:Razoxane; D008936:Mitolactol